PTCT — PTC Therapeutics Balance Sheet
0.000.00%
- $3.91bn
- $5.15bn
- $806.78m
- 41
- 32
- 99
- 58
Annual balance sheet for PTC Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,104 | 773 | 411 | 877 | 1,140 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 69.9 | 110 | 156 | 161 | 159 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 1,232 | 954 | 694 | 1,219 | 1,366 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 118 | 130 | 175 | 179 | 118 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 2,208 | 1,938 | 1,706 | 1,896 | 1,705 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 277 | 509 | 406 | 603 | 581 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 1,726 | 1,937 | 2,053 | 2,714 | 2,803 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 482 | 1.44 | -347 | -819 | -1,098 |
Total Liabilities & Shareholders' Equity | 2,208 | 1,938 | 1,706 | 1,896 | 1,705 |
Total Common Shares Outstanding |